S-1/A: Inspire Veterinary Partners Details Nasdaq Delisting, Dilutive Capital Raise

Sentiment:

Amendment to Registration Statement 28 January 2026 4:27 PM

📋All filings for Inspire Veterinary Partners, INC

Inspire Veterinary Partners, Inc. filed an S-1/A registration statement detailing its delisting from Nasdaq, ongoing financial losses, and plans to raise up to $1.625 million through secured convertible promissory notes.

Delay expectedThe effective date of the registration statement is delayed until a further amendment is filed or the SEC determines it effective.Purchasing real estate with hospital acquisitions brings additional complexity and cost, such as building inspections, zoning requirements, and permitting variabilities, all of which have the potential to cause delays with the purchase of acquisitions and increase the costs of acquiring target locations.

Capital raiseThe filing relates to the potential offer and resale of up to 200,000,000 shares of Class A common stock by a selling stockholder, from which the company will not receive any proceeds.These shares are issuable upon conversion of a secured convertible promissory note (First Note) with an aggregate principal amount of $975,000, issued December 31, 2025.Includes 2,000,000 shares of Common Stock issued as additional consideration for the First Note.Up to 79,000,000 shares of Common Stock are issuable upon conversion of a secured convertible promissory note (Second Note) with an aggregate principal amount of up to $650,000, which will be issued upon the registration statement becoming effective.Includes 500,000 shares of Common Stock to be issued as additional consideration for the Second Note.The Notes are convertible at the option of the Selling Stockholder at a conversion price equal to the lesser of $0.06 per share or 80% of the lowest traded price during the fifteen consecutive trading days prior to conversion, subject to a floor price of $0.01 per share, indicating potential for substantial dilution.The company issued Series B convertible preferred stock and accompanying warrants for aggregate proceeds of approximately $6 million in July and September 2025.A Common Stock Purchase Agreement was entered into with Seven Knots, LLC on July 29, 2025, for up to $50 million of Class A common stock, at the company's discretion.Senior Convertible Promissory Notes were issued to two investors on November 5, 2025, each in the principal amount of $178,571.43 (purchase price $125,000 due to 30% OID), bearing 10% interest, maturing August 5, 2026.Original Issue Discount Notes were issued to Diagonal Lending LLC ($204,700 principal) and Boot Capital LLC ($92,000 principal) on May 30, 2025, for general working capital, maturing March 30, 2026.Merchant Cash Advance Agreements were entered into on October 6, 2025 ($525,000 gross proceeds) and October 22, 2025 ($1,050,000 gross proceeds).

Worse than expectedThe company was delisted from Nasdaq due to non-compliance with minimum bid price and prior reverse stock splits, indicating significant operational and market challenges.Independent auditors raised "substantial doubt" about the company's ability to continue as a going concern due to recurring losses and negative working capital, highlighting severe financial instability.Total revenue for the nine months ended September 30, 2025, decreased by 8% compared to the same period in 2024, indicating a decline in overall business performance despite some quarterly improvements.The company continues to operate at a net loss, with an accumulated deficit of $44,326,159 as of September 30, 2025, demonstrating a persistent inability to achieve profitability.

Summary

The filing is an Amendment No. 1 to Form S-1 Registration Statement, filed on January 28, 2026.
It relates to the potential offer and resale of up to 200,000,000 shares of Class A common stock by a selling stockholder, Manetto Hill Fund Series I, LLC.
These shares are issuable upon conversion of secured convertible promissory notes (First Note: $975,000 principal, Second Note: up to $650,000 principal) and as additional consideration (2,000,000 shares for First Note, 500,000 shares for Second Note).
The company will not receive any proceeds from the sale of Common Stock by the Selling Stockholders.
The company was delisted from Nasdaq on January 21, 2026, due to non-compliance with the minimum bid price requirement and prior reverse stock splits; it now trades on the OTCQB Venture Market under the symbol IVPR.
Authorized Class A Common Stock was increased to 700,000,000 shares on January 9, 2026.
The company cancelled $150,000 of debt with Target Capital 1 LLC in exchange for 3,000,000 shares of Common Stock on December 18, 2025 (at $0.05/share).
An additional $250,000 of debt with Target Capital 1 LLC was cancelled in exchange for 25,000,000 shares of Common Stock on January 14, 2026 (at $0.01/share).
9,450,000 shares of Common Stock were issued to 622 Capital LLC for business development consulting services on December 12, 2025.
A net loss of $7,975,878 was reported for the nine months ended September 30, 2025, an improvement from $10,297,539 for the same period in 2024.
Total revenue decreased by 8% to $12,238,875 for the nine months ended September 30, 2025, from $13,270,973 in 2024.
For the three months ended September 30, 2025, net loss decreased by 28% to $2,526,273 from $3,489,326 in 2024.
Total revenue increased by 7% to $4,316,132 for the three months ended September 30, 2025, from $4,049,025 in 2024.
The company had an accumulated deficit of $44,326,159 and negative working capital of $5,894,301 as of September 30, 2025.
Independent auditors included an explanatory paragraph regarding "substantial doubt" about the company's ability to continue as a going concern.
The company currently operates fourteen veterinary hospitals located in nine states.
DeBary Animal Clinic was acquired on June 4, 2025, for approximately $1,942,500 ($1,850,000 cash, $92,500 in Class A common stock).
Kauai Veterinary Clinic (KVC) was divested on September 20, 2024, for $2.0 million in notes payable assumed by the buyer, resulting in a gain of $467,049.
Series B convertible preferred stock and warrants were issued for aggregate proceeds of approximately $6 million in July and September 2025.
A Common Stock Purchase Agreement was entered into with Seven Knots, LLC on July 29, 2025, for up to $50 million of Class A common stock, at the company's discretion.

Sentiment

Score: 2

Explanation: The company faces significant financial challenges, including recurring losses, negative working capital, and a going concern warning from auditors. The Nasdaq delisting and reliance on highly dilutive financing mechanisms further underscore its precarious position, despite some recent quarterly revenue growth. The overall financial health and market position are weak.

Positives

Net loss decreased by 23% to $7,975,878 for the nine months ended September 30, 2025, compared to $10,297,539 for the same period in 2024.
Net loss decreased by 28% to $2,526,273 for the three months ended September 30, 2025, compared to $3,489,326 for the same period in 2024.
Total revenue increased by 7% to $4,316,132 for the three months ended September 30, 2025, compared to $4,049,025 for the same period in 2024.
Service revenue increased by 6% and product revenue increased by 9% for the three months ended September 30, 2025.
The company successfully acquired DeBary Animal Clinic in June 2025 for approximately $1.94 million.
The divestiture of Kauai Veterinary Clinic in September 2024 resulted in a gain of $467,049.
Nasdaq notified the company on August 26, 2025, that it complies with the minimum stockholders' equity requirement after the first Series B preferred stock closing.
Interest expense decreased by 51% for the nine months ended September 30, 2025, and 55% for the three months ended September 30, 2025.
General and administrative expenses decreased by 7% for the nine months ended September 30, 2025, and 19% for the three months ended September 30, 2025.

Negatives

The company was delisted from Nasdaq on January 21, 2026, and now trades on the OTCQB Venture Market, which typically has reduced liquidity and increased volatility.
Recurring operating losses since inception, with an accumulated deficit of $44,326,159 as of September 30, 2025.
Negative working capital of $5,894,301 as of September 30, 2025.
Independent auditors included an explanatory paragraph regarding "substantial doubt" about the company's ability to continue as a going concern.
Total revenue for the nine months ended September 30, 2025, decreased by 8% compared to the same period in 2024.
Significant dilution risk for existing stockholders due to variable-price conversion features of new secured convertible promissory notes and potential future equity issuances.
High effective interest rates on merchant cash advance agreements (e.g., 42% on the May 20, 2025, amendment).
Management has limited experience as senior management of a public company, which could divert attention and increase compliance costs.
Non-independent directors, officers, and their affiliates control approximately 32% of the voting power, potentially influencing corporate actions against other investors' interests.
The company does not intend to pay cash dividends for the foreseeable future.
Shares are subordinate to all debts and liabilities, increasing the risk of losing the entire investment.
The board can designate and issue new classes of stock (e.g., Class B with 25 votes/share, Preferred Stock) that could dilute or adversely affect Class A holders.

Risks

The company has a limited operating history, is not profitable, and may never become profitable.
The company may need to raise additional capital to achieve its goals, which may not be available on acceptable terms or at all, potentially leading to dilution or restrictive debt covenants.
The company incurs significant increased expenses and administrative burdens as a public company.
Failure to attract and keep senior management could impact the successful integration of acquisitions, scaling services, and customer service.
Failure to manage growth effectively could harm the brand, business, and operating results.
Acquisitions or strategic alliances may be unsuccessful or difficult to integrate, leading to adverse effects.
Acquiring other businesses may be unsuccessful and could dilute ownership.
The ability to use net operating loss carryforwards may be limited by the inability to generate future taxable income or by ownership changes (Code Section 382).
Management lacks extensive public company experience, potentially diverting attention and increasing costs.
Failure to maintain effective internal controls over financial reporting could have a material adverse effect.
Purchasing real estate with hospital acquisitions adds complexity and cost.
The estimate of the addressable market size may be inaccurate.
The company may experience difficulties recruiting and retaining skilled veterinarians due to shortages.
Negative publicity from claims of improper animal care could adversely affect public perception and reduce sales and profitability.
Quarterly operating results may fluctuate due to the timing of expenses, acquisitions, closures, and other factors.
The business may be harmed if computer network security or databases containing personal information are compromised.
The animal health industry is highly competitive.
The company may be unable to adequately protect its intellectual property rights.
The company may be subject to litigation.
Natural disasters and other events beyond control could harm the business.
Various government regulations could limit or delay the ability to develop and commercialize services or negatively impact the business.
Failure to comply with governmental regulations or the expansion of new laws could adversely affect the business or lead to fines and litigation.
The company may fail to comply with regulations covering the dispensing of prescription pet medications, including controlled substances.
The company is subject to environmental, health, and safety laws and regulations that could result in costs.
The Common Stock was delisted from Nasdaq and now trades on the OTCQB Venture Market, leading to limited market quotations, reduced liquidity, potential "penny stock" designation, decreased analyst coverage, and difficulty raising future capital.
Investors buying shares at different times will likely pay different prices and experience different levels of dilution.
If securities or industry analysts do not publish research or issue adverse opinions, the stock price and trading volume could decline.
The company does not intend to pay cash dividends for the foreseeable future.
Shares are subordinate to all debts and liabilities, increasing the risk of losing the entire investment.
The board of directors may designate and issue new classes of stock (e.g., Class B with 25 votes/share, Preferred Stock) that could be superior to or adversely affect Class A holders.
Non-independent directors, officers, and affiliates control approximately 32% of the voting power, potentially influencing corporate actions against other investors' interests.
The trading price of the Common Stock is volatile.
The sale or availability for sale of substantial amounts of Common Stock could adversely affect the market price.
As an emerging growth company and smaller reporting company, reduced disclosure requirements may make Common Stock less attractive to investors.

Future Outlook

The company expects to continue incurring net losses for the foreseeable future as it develops and acquires veterinary hospitals. It intends to restart acquisition activities, targeting five units per year, and may expand into emergency and mixed animal care. Future funding will be sought through debt or equity financing, which may result in dilution or restrictive covenants. The company plans to expand its service offering to include tele-veterinarian services, which will require significant investments in information technology and training.

Management Comments

Management believes our continued success is largely dependent on positive perceptions of our company as a high-quality employer and operator within the veterinary space.
Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern.

Industry Context

The animal health industry is highly competitive and fragmented, with over 28,000 veterinary hospitals in the U.S. and less than 25% consolidated. Competitors range from large national consolidators like Mars and NVA (collectively owning approximately 4,000 hospitals) to regional groups. The company aims to differentiate itself through broad employee equity offerings, a personalized acquisition and integration approach, customized coaching and development for clinicians, and a conservative valuation process based on a 3-year look back and enterprise values designed for long-term ROI.

Comparison to Industry Standards

The company aims for 70% to 80% of gross revenue from services, aligning with industry targets to protect against disruption from other channels.
Uses Revenue Per Patient Per day (RPP) and Average Patient Charge (APC) as "quality medicine metrics" to analyze comprehensive diagnostics and services, ensuring caseload is revenue positive and clinicians' time is utilized effectively.
The valuation of client lists uses an industry standard retention rate of 74.0% for veterinary services.
The company notes that over 28,000 veterinary hospitals exist in the U.S., with less than 25% consolidated, indicating a large addressable market for acquisitions.
Competitors like Mars and NVA collectively own approximately 4,000 hospitals, highlighting the scale of larger players in the fragmented market.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chair of the Board, President and Chief Executive Officer	N/A	Kimball Carr	2025-05-01	Mr. Carr assumed the role of Chair of the Board in May 2025. A new employment agreement was effective February 10, 2025.
Chief Financial Officer	N/A	Richard Frank	2023-01-01	Mr. Frank joined the company in January 2023. A new employment agreement was effective March 1, 2025.
Chief People Officer	Vice President of Human Resources	Lynley Kees	2025-04-01	Promotion from Vice President of Human Resources.
Vice President of Operations	N/A	Laura Johnson	2024-09-01	Joined the company in September 2024.
Director	N/A	Phillip Balatsos	2024-10-01	Joined the Board.
Director	Peter Lau	N/A	2024-10-09	Ceased to serve on the Board.
Director	John Suprock	N/A	2024-10-09	Ceased to serve on the Board.
Director	Timothy Watters	N/A	2026-01-06	Resigned from the Board.
Chief Operating Officer	Charles Stith Keiser	N/A	2023-11-01	Charles Stith Keiser ceased serving as COO in November 2023, but remains a Director.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Composition	The Board currently consists of six members, with a majority being independent directors. The Board has three standing committees (Audit, Compensation, and Governance and Nominating), all comprised of independent directors with independent chairs.	N/A	A majority of independent directors and independent committees generally enhance oversight, but the absence of an Audit Committee Financial Expert and combined CEO/Chair roles could be areas of concern.
Board Leadership Structure	The roles of Chief Executive Officer and Chair of the Board are combined, with Kimball Carr serving in both capacities. The Board believes this structure effectively uses Mr. Carr's experience and provides unified leadership.	N/A	While providing unified leadership, combining these roles can reduce independent oversight and increase the risk of conflicts of interest. The Board evaluates this structure annually.
Authorized Capital Stock	The number of shares of Common Stock authorized for issuance was increased to 700,000,000.	2026-01-09	This increase provides flexibility for future equity raises and conversions but also enables significant potential dilution for existing shareholders.
Voting Power Concentration	Non-independent directors, officers, and their affiliates control approximately 32% of the voting power of outstanding common stock, with Charles Stith Keiser controlling approximately 27.6% through Wilderness Trace Veterinary Partners, LLC.	N/A	This concentration of voting power allows a significant influence over corporate actions, potentially at odds with the interests of other investors, and could hinder independent decision-making.
Anti-Takeover Provisions	Nevada law provisions apply, including removal of directors by two-thirds vote, board filling vacancies, no shareholder right to call special meetings, board amending bylaws, interested stockholder statutes, and acquisition of controlling interest statutes.	N/A	These provisions make hostile takeovers or changes of control more difficult, potentially entrenching current management and reducing shareholder influence over strategic decisions.
Hedging and Pledging Policy	The company has not adopted a policy prohibiting directors, officers, and employees from engaging in short-term or speculative transactions (e.g., short selling, options) or holding stock in margin accounts or pledging stock as collateral.	N/A	The absence of such a policy could expose the company and its shareholders to risks associated with insider trading, conflicts of interest, and potential forced sales of stock due to margin calls, which could negatively impact stock price stability.

Legal Proceedings

No pending legal proceedings against the company or its subsidiaries as of the filing date.
A lawsuit has been initiated in Ohio State Court against a former owner of an animal clinic for violating a non-compete agreement, with anticipation of a favorable judgment for compensation below a certain threshold.

Related Party Transactions

Charles Stith Keiser (director, former COO, largest shareholder) and his father advanced $300,000 to the company for working capital in August 2022, which was repaid prior to the IPO.
Blue Heron Consulting (BHC), where Charles Stith Keiser is COO and his father is Chief Visionary Officer, provided acquisition, business, and financial advisory services. The BHC Consulting Agreement was terminated in Q4 2023, but the company continues to use BHC for ad hoc services, incurring $94,043 in expenses for the nine months ended September 30, 2025, and $83,168 for the year ended December 31, 2024.
Star Circle Advisory Group, LLC, partially owned and controlled by Kimball Carr (CEO), served as a financial consultant. The service agreement was terminated in Q4 2023. The company incurred $284,900 in expenses for the year ended December 31, 2023.
Kimball Carr (CEO) received a warrant on January 1, 2023, to purchase up to 20 shares of Class A common stock at $6,000 per share for his personal guaranty of company loans.
The sale of Kauai Veterinary Clinic (KVC) on September 20, 2024, was to Kauai RE Holdings LLC, where Charles Keiser, DVM (father of board member Charles Stith Keiser) is a member.
Kimball Carr guarantees borrowings under the Master Lending and Credit Facility with FNBD, FSB commercial loans, and merchant cash advance agreements.

Stakeholder Impact

**Shareholders**: Face significant dilution risk from convertible notes and future equity raises; delisting to OTCQB reduces liquidity and market visibility; no dividends expected; Class A shares are subordinate to debt; potential for the board to issue superior stock classes; non-independent directors control significant voting power.
**Employees**: Potential impact from staffing shortages of veterinarians and technicians; benefits from an Employee Stock Option Plan (a stated differentiator); potential for labor disputes.
**Customers**: Continued provision of veterinary services; potential for expanded service offerings (emergency, mixed animal care, tele-veterinarian services); risk of negative publicity affecting the perception of animal care quality.
**Creditors**: Secured convertible notes and other debt obligations are guaranteed by the CEO; the company has recurring losses and going concern doubt, increasing credit risk.
**Suppliers**: No specific impact mentioned, but the company's overall financial health and operational stability could indirectly affect supplier relationships.

Next Steps

The registration statement needs to become effective for the Second Note to be issued and for the Selling Stockholder to resell shares.
The company intends to continue filing periodic and current reports with the SEC.
Management plans to continue seeking additional funding through debt or equity financing.
The company expects to restart acquisition activities, targeting five units per year.
The company may expand service offerings to include emergency care and mixed animal care.
The company will continue to evaluate inputs used in valuations based on quantitative and qualitative information.
The company is addressing a lawsuit against a former employee for violating a non-compete agreement in Ohio State Court.

Key Dates

Date	Description
2020-12-02	Company incorporated in Delaware.
2021-01-25	Acquired Kauai Veterinary Clinic.
2021-06-25	Entered into Master Line of Credit Loan Agreement (MLOCA) with WealthSouth.
2021-08-20	Acquired Chiefland Animal Hospital.
2021-10-07	Acquired Pets & Friends Animal Hospital.
2021-12-31	Entered into two bridge loans for $2,500,000.
2022-01-14	Acquired Advanced Veterinary Care of Pasco.
2022-01-24	Issued warrants to Bridge Lenders.
2022-03-15	Acquired Lytle Veterinary Clinic.
2022-03-22	Acquired Southern Kern Veterinary Clinic.
2022-05-18	Acquired Bartow Animal Clinic.
2022-06-15	Acquired Dietz Family Pet Hospital.
2022-06-29	Company converted to Nevada C-corporation.
2022-07-29	Acquired Aberdeen Veterinary Clinic.
2022-08-12	Acquired All Breed Pet Care Veterinary Clinic.
2022-08-18	MLOCA amended.
2022-09-01	Issued Carr Warrant to Kimball Carr.
2022-10-18	Shareholders approved 2022 Equity Incentive Plan.
2022-10-31	Acquired Pony Express Veterinary Hospital.
2022-11-18	Entered into Original Issue Discount Secured Convertible Note loan with Target Capital 1, LLC.
2022-11-18	Entered into Original Issue Discount Secured Convertible Note with 622 Capital LLC.
2022-12-09	Acquired Williamsburg Animal Clinic.
2022-12-16	Acquired The Old 41 Animal Hospital.
2023-01-01	Issued warrant to Kimball Carr.
2023-02-27	Issued $650,000 in 2023 Convertible Debenture (first date in range).
2023-03-10	Issued $650,000 in 2023 Convertible Debenture (last date in range).
2023-05-30	Entered into Merchant Cash Advance Agreement for $1,050,000.
2023-06-06	First payment due on Merchant Cash Advance Agreement.
2023-06-30	Entered into exchange agreements with Bridge Note lenders for Series A Preferred Stock.
2023-08-10	Amended Merchant Cash Advance Agreement.
2023-08-29	Effective date of registration statement for IPO.
2023-08-31	Completed initial public offering (IPO) and issued Spartan IPO Warrant.
2023-11-08	Acquired Valley Veterinary Service.
2023-11-28	Amended Merchant Cash Advance Agreement.
2023-11-30	Entered into common stock purchase agreement with Tumim Stone Capital LLC.
2023-12-28	Amended agreement with Tumim Stone Capital LLC.
2024-01-01	Richard Frank's employment agreement effective.
2024-01-02	Issued 20,000 shares of Series A preferred stock to Target Capital 1, LLC.
2024-01-18	Amended Merchant Cash Advance Agreement.
2024-01-30	Issued 20 shares of Class A common stock to TraDigital Marketing Group.
2024-02-13	Issued prefunded warrant to an Investor (Tumim).
2024-02-14	Issued 12,143 shares of Class A Common stock to an Investor (Tumim).
2024-03-06	Issued 746 shares of Class A common stock to Charles Chuck Keiser, DVM.
2024-03-25	Stockholder approval obtained for Tumim agreement.
2024-03-26	Entered into securities purchase agreement for $500,000 convertible note payable.
2024-04-04	Entered into new financing agreement for $420,000.
2024-04-08	First payment due on new financing agreement.
2024-05-07	Amended Merchant Cash Advance Agreement.
2024-05-08	Effected 100-for-1 reverse stock split.
2024-06-11	Entered into securities purchase agreement for two $250,000 convertible notes payable.
2024-07-07	Kimball Carr's Employment Agreement extended to February 1, 2025.
2024-09-20	Completed divestiture of Kauai Veterinary Clinic.
2024-09-26	Non-employee directors received options to acquire Class A common stock.
2024-10-09	Peter Lau and John Suprock ceased to serve on the Board.
2024-10-31	Phillip Balatsos joined the Board.
2024-12-24	Amended Merchant Cash Advance Agreement.
2025-01-27	Effected 25-for-1 reverse stock split.
2025-02-10	New employment agreement with Kimball Carr effective.
2025-02-26	Entered non-binding LOI for animal hospital acquisition.
2025-03-01	New employment agreement with Richard Frank effective.
2025-03-25	Entered into securities purchase agreement with institutional investor for registered direct offering.
2025-04-01	Lynley Kees served as Chief People Officer.
2025-04-10	Received Nasdaq notice letter regarding minimum stockholders' equity.
2025-05-20	Amended Merchant Cash Advance Agreement.
2025-05-30	Issued Original Issue Discount Notes to Diagonal Lending LLC and Boot Capital LLC.
2025-06-04	Acquired DeBary Animal Clinic.
2025-06-10	Issued promissory note to Target Capital LLC.
2025-06-30	Issued second promissory note to Target Capital LLC and entered into consulting agreement with Mark Crone.
2025-07-02	Entered into consulting agreement with Alchemy Advisory, LLC.
2025-07-28	Entered into Securities Purchase Agreement for Series B convertible preferred stock and warrants.
2025-07-29	Completed first closing of Series B private placement and entered into Common Stock Purchase Agreement with Seven Knots, LLC.
2025-07-30	Shares issued to Mark Crone.
2025-08-19	Amended promissory notes issued to Target Capital 1 LLC.
2025-08-26	Nasdaq notified compliance with minimum stockholders' equity.
2025-09-09	Completed additional closing of Series B private placement.
2025-09-20	Laura Johnson served as Vice President of Operations.
2025-10-06	Entered into Merchant Cash Advance Agreement for $525,000.
2025-10-17	First payment due on Merchant Cash Advance Agreement.
2025-10-22	Entered into additional Merchant Cash Advance Agreement for $1,050,000.
2025-10-31	First payment due on additional Merchant Cash Advance Agreement.
2025-11-05	Issued Senior Convertible Promissory Notes to two investors.
2025-11-13	Received Nasdaq notice letter regarding minimum bid price.
2025-11-20	Deadline to appeal Nasdaq delisting.
2025-11-24	Nasdaq suspension date (stayed by hearing request).
2025-11-30	Initial payment due on Diagonal Note and Boot Note.
2025-12-01	Agreed to lower Series B Floor Price to $0.05.
2025-12-04	Amended promissory notes to Target Capital 1 LLC to lower Floor Price to $0.05.
2025-12-12	Entered into Consulting Agreement with 622 Capital LLC.
2025-12-18	Entered into Cancellation and Exchange Agreement with Target Capital 1 LLC.
2025-12-31	Issued First Note for $975,000 principal.
2026-01-06	Timothy Watters resigned from the Board.
2026-01-09	Filed certificate of amendment to increase authorized Class A Common Stock to 700,000,000.
2026-01-13	Hearing held with Nasdaq Hearings Panel.
2026-01-14	Entered into second Cancellation and Exchange Agreement with Target Capital 1 LLC.
2026-01-20	Nasdaq Panel denied request to continue listing.
2026-01-21	Common Stock suspended from trading on Nasdaq and began trading on OTCQB Venture Market.
2026-01-28	S-1/A filing date.
2026-01-29	Maturity date for Valley Vet commercial loan with FSB.
2026-03-30	Maturity date for Diagonal Note and Boot Note.
2026-06-03	DeBary Animal Clinic holdback contingency date.
2026-07-01	Maturity date for Ushjo Commercial Loan.
2026-08-05	Maturity date for Senior Convertible Promissory Notes.
2026-12-31	Maturity date for First Note.
2027-06-03	DeBary Animal Clinic holdback contingency date.
2028-01-01	Expiration date for Kimball Carr's warrant.
2028-06-30	Expiration date for warrants held by Target Capital 1, LLC, Dragon Dynamic Catalytic Bridge SAC Fund and 622 Capital LLC.
2028-08-16	Expiration date for Spartan February 2024 Warrant.
2028-12-31	Latest date company may remain an emerging growth company.
2030-03-26	Expiration date for warrants held by institutional investors.
2030-08-29	Expiration date for warrants issued in connection with the initial public offering and held by Spartan Capital Securities, LLC.
2030-09-09	Expiration date for warrants held by institutional investors.
2032-10-18	Expiration date for 2022 Equity Incentive Plan.
2034-09-26	Expiration date for outstanding stock options granted September 26, 2024.
2035-04-01	Expiration date for outstanding stock options granted April 1, 2025.
2035-05-16	Expiration date for outstanding stock options granted May 16, 2025.
2035-05-28	Expiration date for outstanding stock options granted May 28, 2025.

Recommendation

strong sell

The company is in a highly precarious financial position, marked by recurring substantial net losses, negative working capital, and an explicit 'going concern' warning from its independent auditors. The recent delisting from Nasdaq to the less liquid OTCQB Venture Market significantly diminishes market credibility, liquidity, and future capital-raising prospects. While the company has secured some financing, it is largely through highly dilutive convertible notes and preferred stock with variable conversion prices that can exacerbate dilution as the stock price declines. The high effective interest rates on its merchant cash advance agreements further strain its already weak financial health. The concentration of voting power with non-independent directors and the absence of a hedging/pledging policy also raise corporate governance concerns. Given these severe fundamental issues, the stock represents a high-risk investment with a strong likelihood of further value erosion. A seasoned investor would strongly recommend selling.

Keywords

Veterinary, Animal Health, Pet Care, SEC Filing, S-1/A, OTCQB, IVPR, Acquisitions, Convertible Notes, Nasdaq Delisting, Financial Results, Risk Factors, Capital Raise, Small Animal, Equine Care, Going Concern

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.